Taira Deborah A, Tengan Kauilaonālani, Takata Julia, Porter Cody, Ranken Mona Shing, Sentell Tetine L, Seto Todd B
The Queen's Medical Center, Honolulu, HI, USA.
University of Hawai'i at Hilo, 677 Ala Moana Blvd, Suite 1025, Honolulu, Hawai'i, 96813, USA.
Ther Innov Regul Sci. 2025 Aug 30. doi: 10.1007/s43441-025-00867-y.
Clinical trial participation is critical for ensuring new medical treatments are safe and effective for all populations. Native Hawaiian (NH), Pacific Islander (PI), and Filipino individuals experience a disproportionate burden of type 2 diabetes yet remain underrepresented in clinical trials. The primary objective was to generate insights into the motivations, barriers, and communication preferences around clinical trial participation among hospitalized patients from diverse racial/ethnic backgrounds, particularly groups that have been historically underrepresented in research.
We conducted in-person, semi-structured interviews with 56 hospitalized patients at a medical center in Hawai'i. Participants ranked reasons for joining or not joining a clinical trial and responded to open-ended questions. Quantitative data were summarized descriptively. Qualitative responses were analyzed using Rapid Qualitative Analysis and organized by race/ethnicity.
While 84% expressed willingness to join a trial, most had never been asked. NH participants prioritized helping their community and accessing new treatments. PI participants emphasized helping their doctor and advancing science. Filipino participants valued new treatments and contributing to science. White participants ranked financial incentives and community benefit. Major barriers included concerns about unknown medication risks, lack of understanding, and mistrust-particularly among PI and Filipino participants. Many NH and PI participants noted that helping family members was a key motivator. Across all groups, preferred communication strategies included physician referrals, text messaging, and physical mail.
Tailored recruitment strategies emphasizing family and community benefits, involvement of trusted local providers, and culturally relevant communication may enhance clinical trial participation among underrepresented populations with type 2 diabetes.
参与临床试验对于确保新的医学治疗方法对所有人群的安全性和有效性至关重要。夏威夷原住民（NH）、太平洋岛民（PI）和菲律宾人患2型糖尿病的负担不成比例，但在临床试验中的代表性仍然不足。主要目标是深入了解来自不同种族/族裔背景的住院患者参与临床试验的动机、障碍和沟通偏好，特别是在研究中历史代表性不足的群体。
我们在夏威夷的一家医疗中心对56名住院患者进行了面对面的半结构化访谈。参与者对参加或不参加临床试验的原因进行排序，并回答开放式问题。定量数据进行描述性总结。定性回答采用快速定性分析进行分析，并按种族/族裔进行组织。
虽然84%的人表示愿意参加试验，但大多数人从未被邀请过。NH参与者将帮助他们的社区和获得新治疗方法列为优先事项。PI参与者强调帮助他们的医生和推动科学发展。菲律宾参与者重视新治疗方法并为科学做出贡献。白人参与者将经济激励和社区利益列为优先事项。主要障碍包括对未知药物风险的担忧、缺乏理解和不信任，特别是在PI和菲律宾参与者中。许多NH和PI参与者指出，帮助家庭成员是一个关键动机。在所有群体中，首选的沟通策略包括医生推荐、短信和实体邮件。
强调家庭和社区利益、让值得信赖的当地医疗服务提供者参与以及进行文化相关沟通的量身定制的招募策略，可能会提高2型糖尿病代表性不足人群参与临床试验的比例。
Zotero 插件